Fecal microbiota transplantation for the maintenance of remission in patients with ulcerative colitis: A randomized controlled trial

Table 1 The baseline demographics of patients included in the analysis

Baseline variable	All patients (n = 48)		Pvalue	Subgroup A (n = 33)		Pvalue	Subgroup B (n = 15)		Pvalue
	FMT	Placebo		FMT	Placebo		FMT	Placebo
Sex as M/F	14/10	12/12	0.562	8/9	8/8	0.866	4/4	5/2	0.608
Age	43.0 (12.9)	43.1 (12.1)	0.982	43.6 (13.0)	44.8 (12.0)	0.781	41.7 (13.6)	39.8 (12.5)	0.775
Disease duration in mo	39.2 (51.0)	114.0 (117.6)	0.006	41.0 (56.2)	125.4 (121.7)	0.015	34.9 (38.7)	91.3 (113.2)	0.233
Fecal calprotectin	66.0 (108.6)	115.8 (184.7)	0.261	34.7 (46.3)	18.9 (44.9)	0.330	142.3 (172.9)	309.6 (208.3)	0.117
15D	0.903 (0.095)	0.928 (0.072)	0.335	0.899 (0.106)	0.939 (0.070)	0.221	0.915 (0.070)	0.907 (0.078)	0.830
IBDQ	169.4 (28.8)	162.7 (39.8)	0.519	166.9 (28.6)	171.4 (32.0)	0.688	175.0 (30.5)	147.4 (49.3)	0.223

Subgroup A included patients with fecal calprotectin < 200 µg/g and a clinical Mayo score < 3 at baseline, and subgroup B included patients with fecal calprotectin ≥ 200 ug/g or a clinical Mayo score ≥ 3 at baseline. Standard deviations are shown in brackets. M: Male; F: Female; 15D: The total score of the 15 dimensions quality of life questionnaire; IBDQ: The total score of the inflammatory bowel disease quality of life questionnaire; FMT: Fecal microbiota transplantation.